Probiodrug AG announced the appointment of two senior executives: Ronald Black, M.D., chief medical officer, and Inge Lues, Ph.D., chief development officer. Dr. Black will be based in the United States and will lead the company's clinical development strategy and U.S. presence. Dr. Lues will be based in Germany and will be responsible for non-clinical development and ancillary science activities for the company's portfolio of anti-pyroglutamated Abeta therapies for the treatment of Alzheimer's disease.

joining Probiodrug, Dr. Black was assistant vice president of Alzheimer's immunotherapy at Pfizer. For the last five years, Dr. Lues has acted as a research and development advisor to venture capital and biotechnology companies.